J.P. Morgan Roundtable: The Regulatory Role In Accelerating Complex Therapies
Companies working on cell and gene therapies and novel approaches to neurological diseases participated in a roundtable discussion during the J.P. Morgan Healthcare Conference about how regulators are supporting novel modalities, which in turn improves investor and partner sentiment.
You may also be interested in...
It's early days yet and Alzheimer's is a field littered with failures, but the latest results for the vaccine UB-311 support advancing development.
Annual payment plans for gene therapies appear closer to becoming reality now that bluebird bio detailed plans at J.P. Morgan. Novartis, Sarepta and others are also talking to payers about alternative payment models. Harvard Pilgrim's Michael Sherman applauded the effort in an interview.
Scrip caught up with several companies during the recent Cell and Gene Meeting on the Mesa, sponsored by the Alliance for Regenerative Medicine.